证券代码：603520 证券简称：司太立 公告编号：2025-039 浙江司太立制药股份有限公司 关于2025年中期利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例：A 股每股派放现金红利 0.05 元（含税）。 ? 本次利润分配以实施权益分派股权登记日的总股本为基数，具体日期将 在权益分派实施公告中明确。 ? 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总 额不变，相应调整每股分配比例，并将另行公告具体调整情况。 一、公司 2025 年中期利润分配预案 司净利润 65,222,202.48 元。截至报告期末，母公司报表中期末未分配利润为人 民币 625,968,139.74 元。以上数据未经审计。 表决结果：7 票同意、0 票反对、0 票弃权。 三、监事会意见 五届董事会第十七次会议及第五届监事会第十五次会议审议通过了《公司 2025 年中期利润分配预案》，具体内容公告如下： 经董事会研究决定，公司 2025 年半年度中期利润分配方案为：公司拟以实 施权益分 ...

With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Re ...

It has been about a month since the last earnings report for Bausch Health (BHC) . Shares have added about 21.4% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Bausch due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.Bausch Health’s ...

浙江司太立制药股份有限公司2025 年半年度报告摘要 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司拟以实施权益分派股份登记日的总股本为基数，向全体股东每10股派发现金红利0.5元（ 含税）。 以截至 2025年6月30日公司总股本438,409,881股计算合计拟派发现金红利21,920,494.05元（ 含税）。如在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总额不变，相应 调整每股分配比例，并将在相关公告中披露。 第二节 公司基本情况 公司股票简况 公司代码：603520 公司简称：司太立 浙江司太立制药股份有限公司 浙江司太立制药股份有限公司2025 年半年度报告摘要 第一节 重要提示 展规划，投资者应当到 http://www.sse.com.cn 网站仔细阅读半年度报告全文。 股票种类 股票上市交易所 股票简称 股票代码 变更前股票简称 A股 上海证券交易所 司太立 603520 / 联系人和联系方式 董事会秘书 姓名 郭军锋 电话 0576-87718605 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | | --- | --- ...

Key Takeaways J&J is discontinuing Imaavy's RA development after phase IIa results showed no added benefit.The DAISY study tested Imaavy plus anti-TNF aplha in refractory RA but did not improve outcomes.J&J still projects Imaavy as a $5B+ sales driver, with trials ongoing in multiple immune disorders.Johnson & Johnson (JNJ) announced that it is discontinuing the development of an investigational combination therapy involving Imaavy (nipocalimab) in the rheumatoid arthritis (RA) indication.This decision is b ...

Key Takeaways OTLK stock dropped 54.1% after the FDA issued a second CRL for ONS-5010 in wet AMD.The CRL cited insufficient efficacy as ONS-5010 missed the NORSE EIGHT non-inferiority endpoint.OTLK will meet with the FDA for clarity regarding requirements.Shares of Outlook Therapeutics (OTLK) tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related macular degeneration (wet AMD).The CRL cited a s ...

Key Takeaways ABBV offsets Humira losses with Skyrizi and Rinvoq, driving strong sales growth in 2025.MRK leans on Keytruda but faces declining Gardasil sales and other vaccine headwinds.ABBVs rising estimates, robust pipeline and stock gains position it ahead of MRK in 2025.Merck (MRK) and AbbVie (ABBV) are prominent pharmaceutical companies with strong positions in oncology and immunology.AbbVie also operates in aesthetics, neuroscience and eye care, while Merck has a broader focus that includes vaccines, ...

Core Viewpoint - Emergent BioSolutions is re-launching its Ready to Rescue campaign to raise awareness about opioid emergencies and promote the use of NARCAN Nasal Spray among college students, particularly in light of International Overdose Awareness Day [1][5]. Group 1: Campaign Details - The Ready to Rescue campaign will focus on educating young adults about opioid emergencies through events at colleges, particularly targeting Greek Life, wellness services, and athletic departments [1][3]. - Emmitt Smith and Zac Clark will lead discussions to destigmatize opioid poisonings and encourage students to be prepared to use NARCAN Nasal Spray [1][3][6]. - The campaign will provide Ready to Rescue kits containing information on recognizing opioid emergencies and demonstrations on how to use NARCAN Nasal Spray [3][4]. Group 2: Opioid Crisis Statistics - Despite a decline in overdose deaths in 2024, the opioid crisis remains a significant issue, with varying responses across states [2]. - Texas, Illinois, Louisiana, and Michigan have been identified as states needing more support for opioid overdose responses [3]. Group 3: Educational Initiatives - The campaign will also sponsor Mobilize Recovery's Campus Surge initiative, which aims to provide overdose education and harm reduction resources to additional college campuses [4][6]. - Less than 15% of American college students are aware of how to administer naloxone, highlighting the need for increased education and resources [4]. Group 4: Company Mission - Emergent BioSolutions is committed to reducing the impact of the opioid crisis and ensuring access to NARCAN Nasal Spray, aiming to protect vulnerable communities like college students [5][9].

– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence – – Guideline Recognition of ‘Strike Early and Strike Strong’ Approach with Early Combination Lipid-Lowering Therapy Affirms Continued Development of Company’s Oral Triple Combination Therapies in U.S. – ANN ARBOR, Mich., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today welcomed the inclusion of bempedoic acid as the only non-statin newly recommended for LDL-C lowering an ...

白云山公告，子公司广州白云山汉方现代药业有限公司收到国家药品监督管理局签发的结构甘油三酯 《化学原料药上市申请批准通知书》。该原料药为结构脂肪乳注射液(C6～24)与结构脂肪乳（20%）/氨 基酸（16）/葡萄糖（13%）注射液等制剂的关键原料，适用于肠外营养补充脂肪。2024年，上述制剂 品种国内销售额为11.57亿元。截至公告日，白云山汉方在该项目上已投入研发费用约405万元。此次批 准有助于丰富白云山汉方的药用脂质原辅料产品，提升公司脂质原辅料产品的市场竞争力，但对当期业 绩无重大影响。 ...